4basebio (LON:4BB) Shares Up 0.5% - Should You Buy?

4basebio PLC (LON:4BB - Get Free Report)'s share price traded up 0.5% on Thursday . The company traded as high as GBX 1,028 ($13.87) and last traded at GBX 1,005 ($13.56). 268 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 965 shares. The stock had previously closed at GBX 1,000 ($13.49).

Analysts Set New Price Targets

Separately, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a GBX 1,600 ($21.58) target price on shares of 4basebio in a research report on Thursday, March 13th.

4basebio Trading Up 0.5%

The business's 50 day simple moving average is GBX 1,062.63 and its 200 day simple moving average is GBX 1,124.98. The stock has a market cap of £128.74 million, a price-to-earnings ratio of -1,288.46 and a beta of 1.09. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47.

4basebio (LON:4BB - Get Free Report) last posted its quarterly earnings results on Tuesday, May 27th. The company reported GBX (0.94) (($0.01)) EPS for the quarter. On average, research analysts expect that 4basebio PLC will post -3.43 EPS for the current fiscal year.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.